RSV Vaccine: Protect Your Family | Latest Updates
- A research letter by Karaba adn colleagues highlights a potentially reduced effectiveness of the respiratory syncytial virus (RSV) vaccine among individuals with self-reported immunocompromising conditions.The study, which examined...
- Notably, about 40% of the immunocompromised patients studied did not achieve seroconversion or reach the anticipated threshold of neutralizing antibodies after receiving the RSV vaccine.
- Further research is needed to understand the factors contributing to the lower vaccine response in immunocompromised individuals and to develop strategies to improve protection against RSV in this...
RSV vaccine effectiveness could be reduced for those with immunocompromising conditions: That’s the key takeaway from the latest research. A new study reveals a potentially weak immune response to the RSV vaccine in immunocompromised individuals, with nearly half failing to reach expected antibody levels. This directly contrasts with the high efficacy rates observed in the general older adult population. The findings underscore the need for tailored vaccination strategies. News Directory 3 is following the latest developments in vaccine research. Understand the varying responses to the vaccine, and discover what’s next for protecting vulnerable populations.
Varied RSV Vaccine Response Seen in Immunocompromised Patients
Updated June 12, 2025
A research letter by Karaba adn colleagues highlights a potentially reduced effectiveness of the respiratory syncytial virus (RSV) vaccine among individuals with self-reported immunocompromising conditions.The study, which examined a prospective national cohort, revealed a heterogeneous and often weak immunogenicity response to the vaccine.
Notably, about 40% of the immunocompromised patients studied did not achieve seroconversion or reach the anticipated threshold of neutralizing antibodies after receiving the RSV vaccine. This contrasts with findings from studies on the general older adult population, which reported high overall efficacy rates ranging from 72% to 94% and 62% to 85.7% in two separate evaluations of prefusion F vaccines.
What’s next
Further research is needed to understand the factors contributing to the lower vaccine response in immunocompromised individuals and to develop strategies to improve protection against RSV in this vulnerable population. The findings underscore the importance of tailored vaccination approaches for specific patient groups.